News

An investigator presents final PAPILLON trial results showing long-term survival in a subset of lung cancer

Faecal microbiota transplantation may improve immunotherapy-related colitis

WCLC 2026: Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC

WCLC 2026: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

WCLC 2026: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

WCLC 2026: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer

WCLC 2026: Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC

WCLC 2026: Subcutaneous tarlatamab shows favourable safety profile and antitumour activity in extensive-stage small cell lung cancer

Promising new option for skin cancer reconstruction

Identification PDF as a biomarker of “cold” CRC using integrated bioinformatics and machine learning

AI tool successfully predicts outcomes of immunotherapy in lung cancer

WCLC 2026: Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC